Solid Biosciences to Present at the Jefferies London Healthcare Conference
Solid Biosciences to Present at the Jefferies London Healthcare Conference
CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Combo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET).
2024年11月14日，馬薩諸塞州查爾斯敦，Solid Biosciences Inc.（納斯達克：SLDB）（"公司" 或 "Solid"），一家生命科學公司，致力於爲神經肌肉和心臟疾病開發精準基因藥物，今天宣佈，總裁兼首席執行官Bo Combo和首席醫療官Gabriel Brooks.D.將於2024年11月20日星期三下午1:30，在格林威治標準時間（美國東部時間上午8:30）參加Jefferies倫敦醫療健康大會。
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.
演示的現場網絡廣播可以在公司網站的投資者部分的活動頁面或點擊此處進行觀看。演示的網絡重播將在活動頁面上存檔30天。
Institutional investors interested in meeting with management during the conference may reach out to their Jefferies representatives.
有意在會議期間與管理層會面的機構投資者可以聯繫傑弗里斯的代表。
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid's mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit .
關於固體生物科學（Solid Biosciences）
Solid Biosciences是一家專注於推進基因治療候選品組合，包括SGt-003用於治療肌營養不良(Duchenne)，SGt-501用於治療兒茶酚胺能多形性室性心動過速（CPVT），Avb-401用於治療BAG3介導性擴張性心肌病以及其他治療致命心臟疾病的資產的精準基因藥物公司。Solid正在推進其在罕見神經肌肉和心臟疾病的多樣化管線，彙集了科學、技術、疾病管理和護理方面的專家。受患者關注和直接影響，Solid的宗旨是改善那些正在經歷這些毀滅性疾病的患者的日常生活。請訪問 了解更多信息。
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Solid Biosciences投資者聯繫方式：
Nicole Anderson
投資者關係和企業傳播董事Nicole Anderson
solid biosciences 公司。
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
媒體聯繫：
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
Source: Solid Biosciences Inc.
來源：Solid Biosciences Inc.
譯文內容由第三人軟體翻譯。
